Weaning Off Semaglutide When the Label Has No Taper

No Ozempic or Wegovy label requires a taper or lists withdrawal effects when semaglutide stops (Ozempic and Wegovy prescribing information). One published taper holds Wegovy at 1.7 mg and then 1 mg for 4 to 6 weeks each, stepping down only while weight and appetite stay stable (Brufani and Morviducci, 2025).

Key facts

• Semaglutide stays in the body about 5 weeks after the last Ozempic dose and 5 to 7 weeks after Wegovy (Ozempic and Wegovy prescribing information, section 12.3).
• A Danish online clinic’s taper cuts the semaglutide dose at 4- to 8-week intervals and may go back up after a gain of over 2 kg (Seier et al., 2025).
• Wegovy single-dose pens each deliver one fixed strength, from 0.25 to 7.2 mg, so every taper step needs a new pen (Wegovy prescribing information, section 3).
• After 2 or more missed Wegovy doses in a row, the US label restarts the dose escalation at a lower dose (Wegovy prescribing information, section 2.4).
• A maintenance dose below the maximum is an ADA 2026 option, down to the lowest dose that still works (ADA, 2026).

Can you stop semaglutide cold turkey?

Yes, as far as the labels go. None of the US labels for Ozempic, Wegovy or Zepbound has a drug abuse and dependence section or a withdrawal warning (Ozempic, Wegovy and Zepbound prescribing information). Their dosing sections set out how to start and raise the dose, with no step-down schedule for stopping.

Even after a straight stop, semaglutide leaves the body slowly, because its half-life is about 1 week and its level roughly halves each week after the last shot (Ozempic prescribing information, section 12.3). Tirzepatide’s is about 5 days in the UK Mounjaro Summary of Product Characteristics (SmPC), the UK prescribing document (Mounjaro SmPC, section 5.2). The US Zepbound label gives 5 to 6 days (Zepbound prescribing information, section 12.3).

Each figure is the share of the level just after the last dose, using 7 days for semaglutide and 5 days for tirzepatide.

Each semaglutide row is half the row above it (week 3 is ½ × ½ × ½ = 12.5%). For tirzepatide, a week is 7 ÷ 5 = 1.4 half-lives, so week 1 is ½ to the power 1.4, or 38%. The model ignores the 1 to 3 days a semaglutide injection takes to reach its peak (Ozempic prescribing information, section 12.3), so read the rows as approximate.

The labels give about 5 weeks in the circulation after Ozempic and 5 to 7 weeks after Wegovy 2.4 or 7.2 mg (Ozempic and Wegovy prescribing information, section 12.3). The "4 to 5 weeks" in the Ozempic label is the time semaglutide takes to reach steady state after a dose starts or changes, a separate figure.

For a last Wegovy shot on Monday, October 5, 2026, about half the level is left on October 12, a quarter on October 19 and about 3% on November 9. To see the fall for your own dose, enter your last shot in the GLP‑1 plotter.

Taper schedules and other ways to cut back

We found two published semaglutide tapers, and neither reports measured results for the people who tapered. A Danish online clinic’s protocol lowers the dose every 4 to 8 weeks and may raise it again if weight climbs by more than 2 kg (Seier et al., 2025).

Guideline statements "do not provide formal recommendations for tapering protocols" for GLP‑1 medicines, in the assessment of two clinicians in Rome (Brufani and Morviducci, 2025). Stepping down slowly to a stop appears in the American Diabetes Association’s 2026 obesity standards only for a high-dose medicine that is not working, with no schedule (ADA, 2026).

Their own taper, the second of the two, steps down from Wegovy 2.4 mg and judges each step by the weight trend (for example, less than 2% regain), hunger and fullness. Its authors call the approach anecdotal and untested in randomized trials (Brufani and Morviducci, 2025).

Wegovy’s single-dose pens give one fixed dose each, so the steps mean 1.7 mg pens, then 1 mg pens, then 0.5 mg pens (Wegovy prescribing information, section 3). On Wegovy 7.2 mg, the strength below is 2.4 mg, which the label requires for at least 4 weeks before 7.2 mg (Wegovy prescribing information, section 2.2). Ozempic has one pen for 2 mg doses, one for 1 mg, and one that gives 0.25 or 0.5 mg (Ozempic prescribing information, section 3).

The evidence behind each way of cutting back, as of September 2026, runs from one randomized trial to clinic descriptions (Wong et al., 2026; Horn et al., 2026; ADA, 2026).

A longer gap between doses

In the Scripps Clinic case series, 30 adults whose weight had plateaued on weekly semaglutide or tirzepatide moved to shots mostly every other week, at the same dose (Wong et al., 2026). Over an average of 36.3 weeks, their average weight went from 74.1 kg to 72.4 kg (Wong et al., 2026). Four of the 34 who started went back to weekly shots because of weight regain before their first follow-up and were not analyzed (Wong et al., 2026).

The Ozempic, Wegovy and Zepbound labels give the dose once a week (Ozempic, Wegovy and Zepbound prescribing information, section 2), so a 14-day gap is off-label. A longer gap lets the level fall further before the next shot. The level just before each shot, as a share of the level just after the previous one, is 0.5 to the power (days between shots ÷ half-life in days).

At the same dose, a shot every 14 days also halves the average level over time (the dose ÷ 14 days instead of ÷ 7), the same as halving the weekly dose. We found no trial that compares a longer gap with a taper. You can draw a longer gap against your weekly curve in the GLP‑1 plotter.

Staying on a lower maintenance dose

The American Diabetes Association’s 2026 obesity standards recommend continuing obesity medicines after reaching treatment goals (grade A), at a dose that "may not necessarily be the maximum approved dose" (ADA, 2026). Their options for maintenance include the lowest effective dose, which "may not be an FDA-approved maintenance dose", intermittent therapy, a switch of medicine, or stopping with close monitoring (ADA, 2026).

On the Wegovy label, the maintenance doses for weight reduction are 1.7 mg or 2.4 mg, with 7.2 mg as the maximum (Wegovy prescribing information, section 2.2).

A lower maintenance dose has been tested against stopping in SURMOUNT-MAINTAIN, a randomized trial of tirzepatide. Adults who had lost weight over 60 weeks on 10 or 15 mg stayed on that dose, dropped to 5 mg or switched to placebo for a year (Horn et al., 2026). By week 112, the three groups were 21.9%, 16.6% and 9.9% below their starting weight (Horn et al., 2026). Across the three groups, 8%, 25% and 67% regained at least half of what they had lost and started rescue tirzepatide (Horn et al., 2026).

The Wegovy label also allows a switch to Wegovy tablets, 25 mg once a day, starting one week after the last 2.4 mg injection (Wegovy prescribing information, section 2.5).

After your last dose

A 2025 expert consensus on nutrition and lifestyle care with GLP‑1 medicines gives this advice for when the drug has to stop (Sievenpiper et al., 2025):

• Keep to the diet you followed when you started the medicine.
• Stay in close follow-up, with repeated lifestyle support, to limit regain.
• Do at least 150 minutes a week of moderate to vigorous aerobic activity, plus resistance training.
• Favor calorie-controlled, protein-rich meals, which the panel says may help prevent regain.
• See a registered dietitian where one is available.

The panel graded the exercise point as guideline-based and the rest as expert opinion (Sievenpiper et al., 2025).

Half to two-thirds of the loss came back within a year in STEP 1’s extension, STEP 4 and SURMOUNT-4 (Wilding et al., 2022; Rubino et al., 2021; Aronne et al., 2024). None of the three measured appetite or what the regained weight was made of.

In the SURMOUNT-1 and STEP 1 scan studies, lean mass made up 25 to 39% of the weight lost (Look et al., 2025; Mozaffarian et al., 2025). For the protein-rich part of the advice, you can get a daily target in grams for your weight from the GLP‑1 protein calculator.

The washout and the Wegovy restart rule both count from the date of your last shot, and Pensday keeps that date with every dose you logged.

Restarting semaglutide after stopping

How you restart depends on the brand and the country (Wegovy prescribing information, section 2.4; Wegovy SmPC, section 4.2; Ozempic prescribing information, section 2.1; Ozempic SmPC, section 4.2).

For a last Wegovy shot on Monday, October 5, 2026, missing the doses due October 12 and 19 means restarting at a lower dose on October 26. By then, three weeks after the last shot, about 12.5% of the level is left (½ × ½ × ½).

A single late dose is a different case, with its own missed-dose windows for each brand.

Coming off Wegovy or Mounjaro in the UK

NICE, which decides what the NHS in England funds, recommends Wegovy for at most 2 years within a specialist weight management service (NICE TA875). It says to consider stopping if less than 5% of the initial weight has been lost after 6 months (NICE TA875).

NICE and the Mounjaro SmPC both ask for a decision on continuing tirzepatide if less than 5% is lost after 6 months on the highest tolerated dose (NICE TA1026; Mounjaro SmPC, section 4.2).